Aeglea BioTherapeutics

$7.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (+0.41%) As of 1:31 PM UTC today

Why Robinhood?

You can buy or sell AGLE and other stocks, options, and ETFs commission-free!

About AGLE

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.

CEO
Anthony G. Quinn
Employees
90
Headquarters
Austin, Texas
Founded
2013
Market Cap
355.00M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
127.45K
High Today
$7.28
Low Today
$7.28
Open Price
$7.28
Volume
598.00
52 Week High
$11.38
52 Week Low
$4.91

AGLE Earnings

-$0.68
-$0.45
-$0.23
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 6, Pre-Market

You May Also Like

IGLD
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure